<DOC>
	<DOCNO>NCT00527878</DOCNO>
	<brief_summary>This study examine safety effectiveness ranitidine ( Zantac ) patient Hyper-IgE recurrent infection syndrome , disease characterize recurrent infection ear , sinus , lung skin , abnormal level antibody immunoglobulin E ( IgE ) . Patients age 2 old Hyper-IgE recurrent infection syndrome chronic frequent infection last 12 month may eligible study . Participants randomly assign take ranitidine placebo pill liquid form twice day 12 month . In addition treatment , patient undergo follow procedure visit schedule day 0 study ( baseline ) 3 , 12 , 15 24 month . Evaluations 6 , 9 , 18 21 month telephone . - Medical history physical examination - baseline 3 24 month . - Clinical severity score - baseline 3 , 6 , 9 , 12 , 15 , 18 , 21 24 month . - Dermatology exam - baseline 3 , 12 , 15 24 month . - Pulmonary function test - baseline 12 24 month . - Chest CT - baseline 12 24 month . - Quality life assessment - baseline 3 , 12 , 15 24 month . - Pregnancy test - baseline 3 , 12 , 15 24 month . - HIV test - baseline 12 24 month . - Contraception evaluation - baseline 3 , 6 , 9 , 12 , 15 , 18 , 21 24 month . - Missed school/work day assessment - baseline 3 , 12 , 15 24 month . - Medication adherence - baseline 3 , 6 , 9 , 12 , 15 , 18 , 21 24 month . In addition procedure , participant enrol study 00-I-0159 baseline scoliosis series genetic consult .</brief_summary>
	<brief_title>Effect Ranitidine Hyper-IgE Recurrent Infection ( Job 's ) Syndrome</brief_title>
	<detailed_description>Hyper-immunoglobulin E ( IgE ) syndrome ( HIES ) rare primary immunodeficiency characterize eczema , recurrent skin lung infection , elevate serum IgE , multiple connective tissue skeletal abnormality . The autosomal dominant form HIES cause primarily mutation STAT3 gene . Patients HIES produce IgE antibody specific Candida albicans Staphylococcus aureus , two common pathogen population . We hypothesize presence pathogen-specific IgE , combine continuous exposure ubiquitous agent , lead chronic IgE-mediated histamine release basophils mast cell , subsequent pathogen-specific immune tolerance increase pathogen-specific T regulatory cell . We plan test hypothesis clinical immunologic evaluation HIES patient , , histamine-2 receptor ( H2 ) blocker therapy ranitidine prospective , placebo-controlled crossover study . We choose therapy histamine show stimulate interleukin-10 ( IL-10 ) , major regulatory cytokine , H2 receptor , clinical improvement observe several patient treat H2 blocker . Laboratory study include determination pathogen-specific immunoglobulin G4 ( IgG4 ) : IgE ratio , basophil activation , IL-10 produce regulatory T-cells , cellular proliferative response staphylococcal candidal antigen , functional test regulatory T-cells . Clinical evaluation include comprehensive history physical examination , dermatologic evaluation , genetic evaluation clinical severity score HIES , pulmonary function test , chest computerize tomography ( CT ) examination . Through study , understand immunologic abnormality HIES determine whether large prospective , double-blind trial H2 blockade adjunctive therapy HIES indicate .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Job Syndrome</mesh_term>
	<mesh_term>Ranitidine</mesh_term>
	<mesh_term>Ranitidine bismuth citrate</mesh_term>
	<criteria>INCLUSION CRITERIA : 1 . Male female patient diagnosis Hyper IgE Recurrent Infection ( Job ) syndrome . Mutations STAT3 gene account majority , case HIES . However full genetics HIES remain unknown , use clinical criterion , include expert opinion investigator , well score great 40 diagnostic scoring system use protocol 00I0159 . 2 . A chronic ( great 4 week duration ) infection great 2 acute infection within last 12 month . Acute infection include limited : pneumonia , abscess , sinusitis , skin infection , mucocutaneous candidiasis ear infection . Chronic infection include continuous intermittent symptom despite appropriate therapeutic intervention least 4 week , include limited chronic lung infiltrates productive cough , chronic ear drainage despite topical therapy , chronic intermittent drainage single abscess site , and/or chronic sign sinusitis sinus CT scan . 3 . Patients age 2 year . There upper age limit . We exclude child le 2 year age , expect meet first inclusion criterion , score high enough diagnosed HIES . 4 . Patients personal clinical baseline least 2 week duration . Patients start study medication acute exacerbation infection . 5 . The patient patient 's guardian willing capable providing inform consent initial counsel clinical staff . Separate consent form interventional procedure obtain explanation specific procedure . 6 . Patients must agree blood store future study immune system and/or medical condition . 7 . Women childbearing potential must agree use adequate contraception ( hormonal barrier method birth control ; abstinence ) prior study entry duration study participation . 8 . Patients may concurrently enrol protocol long Principal Investigator ( PI ) inform . EXCLUSION CRITERIA : 1 . Pregnancy . Ranitidine pregnancy class B , likely safe pregnancy , study , pregnant patient exclude . In addition , hormonal change occur pregnancy may affect skin manifestation frequency infection . 2 . Hypersensitivity ranitidine ingredient ranitidine . 3 . Preexisting medication condition investigator judge ranitidine give . 4 . Patient investigator unwilling stop baseline H2 receptor antagonist therapy ( counter prescription ) Tagamet ( Cimetidine ) , Pepcid ( Famotidine ) , Axid ( Nizatidine ) . H2 receptor antagonist therapy must stop 3 month prior study initiation . Patients receive H2 receptor antagonist therapy gastritis , acid reflux , peptic ulcer disease offer change regimen proton pump inhibitor nonH2 receptor antagonist therapy allow study enrollment ( 3 month stop H2 receptor antagonist ) . 5 . Patients age 2 year 6 . Patients HIV , receive chemotherapy malignancy . 7 . Any condition judgment investigator would place subject undue risk compromise result interpretation study .</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>Hyper-IgE Recurrent Infection Syndrome</keyword>
	<keyword>Ranitidine Therapy</keyword>
	<keyword>Job 's Syndrome</keyword>
	<keyword>Cross-Over Study</keyword>
	<keyword>Double-Blind Placebo Controlled</keyword>
	<keyword>Hyper-IgE Syndrome</keyword>
	<keyword>Job Syndrome</keyword>
	<keyword>Immune Deficiency</keyword>
</DOC>